.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Federal Trade Commission
Novartis
Teva
Argus Health
Fish and Richardson
McKinsey
Chinese Patent Office
Farmers Insurance
McKesson

Generated: July 22, 2017

DrugPatentWatch Database Preview

ANTIZOL Drug Profile

« Back to Dashboard

Which patents cover Antizol, and what generic Antizol alternatives are available?

Antizol is a drug marketed by Par Pharm Inc and is included in one NDA. There is one patent protecting this drug.

This drug has nine patent family members in eight countries.

The generic ingredient in ANTIZOL is fomepizole. There are five drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the fomepizole profile page.

Summary for Tradename: ANTIZOL

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list104
Clinical Trials: see list1
Patent Applications: see list1,006
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ANTIZOL at DailyMed

Pharmacology for Tradename: ANTIZOL

Drug ClassAntidote
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Par Pharm Inc
ANTIZOL
fomepizole
INJECTABLE;INJECTION020696-001Dec 4, 1997APRXYesYes7,553,863► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ANTIZOL

Country Document Number Estimated Expiration
Japan5378788► Subscribe
South Korea20080000660► Subscribe
World Intellectual Property Organization (WIPO)2006115626► Subscribe
Japan2008538560► Subscribe
Canada2605413► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Army
Novartis
Teva
Dow
Healthtrust
US Department of Justice
UBS
Boehringer Ingelheim
Queensland Health
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot